Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050999 · ClinicalTrials.gov registry record · Phase 4
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
A Phase 4 study of Mycosis Fungoides and Sezary Syndrome, sponsored by Eisai.
- Completed
- Registry status
- Phase 4
- Development phase
- 195
- Enrollment target
- 20
- Study locations
NCT00050999: Completed Phase 4 study of Mycosis Fungoides and Sezary Syndrome, sponsored by Eisai.
NCT00050999 is a Phase 4 study of Mycosis Fungoides and Sezary Syndrome that has completed, run by Eisai. The registered enrollment target is 195 participants, above the 153-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (27% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050999, a Phase 4 study of Mycosis Fungoides and Sezary Syndrome, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 195 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the effectiveness of two dose levels of ONTAK (denileukin diftitox) in treating patients who have recurrent or persistent cutaneous T-cell lymphoma.
Conditions Studied
Interventions
- DRUG ONTAK
Study Locations (20)
Other
- LKH Universitatsklinikum Graz - Graz
- Allgemeines Krankenhaus der Stadt Wien - Vienna
- Universitatsklinikum Charite - Berlin
- University of Erlangen - Erlangen
- Universitatsklinikum Essen - Essen
- J.W. Goethe University Frankfurt - Frankfurt
- Universitatskrankenhaus Eppendorf - Hamburg
- Universitatsklinikum Mannheim - Mannheim
- Universitatsklinikum Munster - Münster
- Sektion Dermatologische Onkologie - Tübingen
- LUMC, Department of Dermatology - Leiden
- Medical Academy in Gdansk, Dept. of Hematology - Gdansk
New South Wales
- Level 4 Department of Haematology Royal North Shore Hospital - Saint Leonard's
- Westmead Hospital, Department of Haematology - Westmead
Queensland
- Mater Misericordiae Adult Hospital - South Brisbane
- Oncology Haematology Radiation Oncology Unit, Princess Alexandra Hospital - Woolloongabba
Texas
- University of Texas, M.D. Anderson Cancer Center - Houston
Alberta
- Cross Cancer Centre - Edmonton
Ontario
- Hamilton Regional Cancer Center - Hamilton
Quebec
- Jewish General Hospital - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 1995-06 |
| Est. Completion | 2006-12 |
| Phase | Phase 4 |
What the finished NCT00050999 record still lists
NCT00050999 is an interventional study that assigns participants to a tested intervention. The registered 195 participants enrollment target is mid-sized for trials with a published cap, above the 153-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (27% higher).
The record links to 3 conditions, with Mycosis Fungoides appearing as the primary indexed condition, and to 1 intervention - of which ONTAK is the first listed.
NCT00050999 names 20 study sites across 7 states, led by Other, New South Wales, Queensland.
Frequently Asked Questions
What is clinical trial NCT00050999 about?
NCT00050999 is a clinical study titled "Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients". The purpose of this study is to compare the effectiveness of two dose levels of ONTAK (denileukin diftitox) in treating patients who have recurrent or persistent cutaneous T-cell lymphoma.
What is the current status of trial NCT00050999?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 195 participants. The study started on 1995-06. Estimated completion is 2006-12.
What conditions does trial NCT00050999 study?
This clinical trial studies the following conditions: Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous.
What interventions are being tested in trial NCT00050999?
The interventions under investigation include: ONTAK (DRUG).
Who is sponsoring clinical trial NCT00050999?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00050999 being conducted?
This trial has 20 study locations across Texas, New South Wales, Queensland, Alberta, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mycosis Fungoides
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00050999's enrollment target sits among peer trials
195 3rd of 19 higher than 17 of 19 other Mycosis Fungoides trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mycosis Fungoides trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
RECRUITING · Phase 1
-
Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides
RECRUITING · Early Phase 1
-
Photopheresis in Early-stage Mycosis Fungoides
RECRUITING · Phase 2
-
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
RECRUITING · Phase 1
-
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
RECRUITING
-
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276922 · 195 participants · NA
Creative Arts Program to Reduce Burnout in Healthcare Professionals
- NCT04829357 · 195 participants
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
- NCT05054738 · 195 participants · NA
CRP and S&A for Inpatient Veterans
- NCT05561595 · 195 participants · NA
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia